AIM ImmunoTech files prospectus for resale of 31.3 million shares
AIM ImmunoTech filed a prospectus for the resale of up to 31,287,933 shares of common stock by selling stockholders. The offering includes shares issuable upon the exercise of Class H and Class I Warrants, as well as placement agent warrants. The stock is listed on NYSE American under the symbol 'AIM' and was last traded at $0.52 per share on June 5, 2026.
*this image is generated using AI for illustrative purposes only.
AIM ImmunoTech has filed a prospectus for the resale of up to an aggregate of 31,287,933 shares of its common stock by selling stockholders. The shares, with a par value of $0.001 per share, include those issuable upon the exercise of Class H and Class I Warrants, as well as placement agent warrants issued to Ladenburg Thalmann & Co., Inc. The company's common stock is listed on NYSE American under the symbol 'AIM' and was last quoted at $0.52 per share on June 5, 2026.
Breakdown of Shares
The resale offering consists of four distinct categories of shares:
| Share Category | Number of Shares |
|---|---|
| Class H Warrants | 14,903,840 |
| Warrant Inducement Placement Agent Warrants | 894,230 |
| Class I Warrants | 15,038,702 |
| May Offering Placement Agent Warrants | 451,161 |
The Class H Warrants and Warrant Inducement Placement Agent Warrants were issued in connection with a warrant inducement transaction that closed on May 8, 2026. The Class I Warrants and May Offering Placement Agent Warrants were issued in connection with a registered direct offering and concurrent private placement that closed on May 21, 2026.
Warrant Details
The Class H and Class I Warrants are collectively referred to as the 'Warrants,' while the placement agent warrants are referred to as the 'Placement Agent Warrants.' The shares underlying the Warrants are called 'Warrant Shares,' and those underlying the Placement Agent Warrants are called 'Placement Agent Warrant Shares.' Ladenburg Thalmann & Co., Inc. served as the placement agent for both transactions.
How might the resale of over 31 million shares impact AIM ImmunoTech's stock price in the short term?
What are the potential implications for future capital raising if current stockholders choose to sell their shares?
Could this resale signal a lack of confidence among early investors, or is it a routine liquidity event?
18
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
